[1] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2] Chen W, Zheng R, Baade P D, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[3] Chan ACY, Poon RTP, Cheung TT, et al.Laparoscopic versus open liver resection for elderly patients with malignant liver tumors: A single-center experience[J]. J Gastroenterol Hepatol, 2014, 29(6): 1279-1283
[4] Cheung TT, Ronnie TP, Poon T, et al.Outcome of laparoscopic versus open hepatectomy for colorectal liver metastases[J]. ANZ J Surg, 2013, 83(11): 847-852.
[5] Wan PT, Garnett MJ, Roe SM, et al.Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutationsof B-RAF[J]. Cell, 2004, 116(6): 855-867.
[6] De Roock W, Claes B, Bernasconi D, et al.Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy ofcetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectalcancer: a retrospective consortium analysis[J]. Lancet Oncol, 2010, 11(8): 753-762.
[7] Margonis G A, Buettner S, Andreatos N, et al.Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer[J]. Jama Surg, 2018, 153(7): e180996.
[8] Ayez N, van der Stok EP, Grünhagen DJ, et al. The use of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator[J]. Eur J Surg Oncol, 2015, 41(7): 859-867.
[9] Carbone D P, Reck M, Paz-Ares L, et al.First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2017, 376(25): 2415-2426.
[10] Roth AD, Tejpar S, Delorenzi M, et al.Prognostic role of KRAS and BRAF in stage II and III resected colon cancer:results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00trial[J]. J Clin Onco, 2010, 28(3): 466-74.
[11] Schirripa M, Bergamo F, Cremolini C, et al.BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection[J]. Brit J Cancer, 2015, 112(12): 1921-1928.
[12] SafiShahda, AnneM. Noonan, TaniosS, et al. Aphase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer[J]. JClinOncol, 2017, 35(15_suppl): 3541.
[13] Galluzzi L, Zitvogel L, Kroemer G.Immunological Mechanisms Underneath the Efficacy of Cancer Therapy[J]. Canc Immun Res, 2016, 4(11): 895-902.
[14] Tabernero J, Grothey A, Van Cutsem E, et al. Encorafenib plus cetuximab with or without binimetinib for BRAF-mutant metastatic colorectal cancer: Expanded results from a randomized,3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)[J]. ESMO2019, abstract LBA 32
[15] Wanis K N, Pineda-Solis K, Tun-Abraham M E, et al. Management of colorectal cancer with synchronous liver metastases: impact of multidisciplinary case conference review[J]. Hepat Surg Nut, 2017, 6(3): 162-169. |
